Loading
LBL-034 is an experimental bispecific T-cell engager from Nanjing Leads Biolabs, in phase 2 trials for multiple myeloma.
LBL-034 is a bispecific T-cell engager (2:1 format) from Nanjing Leads Biolabs. A T-cell engager with two binding sites for GPRC5D and one for CD3 that directs T cells to GPRC5D-positive myeloma cells. Its furthest stage is phase 2, for multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Phase I/II trial in relapsed/refractory multiple myeloma in China (NCT06049290, recruiting). FDA Orphan Drug (Oct 2024) and Fast Track (Jan 2026) per company. Whether it works in people has not been established unless a trial below reports it.
1.One arm of LBL-034 binds GPRC5D on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LBL-034" OR ABSTRACT:"LBL-034") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LBL-034, not a curated reading list.
Shares GPRC5D, Multiple myeloma and the tag pipeline.
Shares GPRC5D and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/